What we do
The Clinical Translation Pathway (CTP) supports innovative cancer research that aims to turn scientific discoveries into tools to find cancer earlier and treat it more effectively.

Why we do it
New findings in the lab don’t easily become new practices in the clinic. There are many challenges in turning scientific discoveries into tools and treatments that benefit patients. OICR created CTP to help overcome these challenges and deliver impactful and cost-effective cancer solutions to patients who need them.

How we do it
CTP supports a wide range of cancer innovative research, including innovations from OICR-supported research as well as projects from across Ontario. The program focuses on projects with a clear path to impact, helping research findings be adopted into practice. By encouraging the collaboration between researchers, patients, and caregivers, the CTP embodies the principles of equality, diversity, and inclusion (EDI).

Funding Streams

• Pre-Clinical Acceleration Team Awards (Pre-CATA): Supports pre-clinical projects, which are early stage studies before innovations are tested with humans, with a focus on the discovery of biomarkers, diagnostics and therapeutics.
• Clinical Acceleration Team Awards (CATA): Supports early phase (I-II) clinical trials for the validation of biomarkers, diagnostics and therapeutics in humans.